Cryoport reports fourth quarter and full year 2024 financial results

Fy 2024 revenue of $228.4 million, in-line with company guidance commercial cell & gene therapy revenue rose to $26 million in fy 2024, up 20% year-over-year supporting a record total of 701 global clinical trials as of december 31, 2024 nashville, tenn. , march 4, 2025 /prnewswire/ -- cryoport, inc. (nasdaq: cyrx) (cryoport), a global leader in supply chain solutions for the life sciences industry, today announced financial results for the fourth quarter (q4) and year ended (fy) december 31, 2024.
CYRX Ratings Summary
CYRX Quant Ranking